Review

Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines

Elnaz Faghfuri

Elnaz Faghfuri

*Author for correspondence: Tel.: +98 914 105 2527;

E-mail Address: Elnaz.faghfuri@gmail.com

https://orcid.org/0000-0003-2002-2525

Digestive Disease Research Center, Ardabil University of Medical Sciences, Ardabil, 5613658115, Iran

Search for more papers by this author

Published Online:13 Dec 2023https://doi.org/10.2217/pme-2023-0054

View article

Abstract

The results of genomic and molecular profiling of cancer patients can be effectively applied to immunotherapy agents, including immune checkpoint inhibitors, to select the most appropriate treatment. In addition, accurate prediction of neoantigens facilitates the development of individualized cancer vaccines and T-cell therapy. This review summarizes the biomarker(s) predicting responses to immune checkpoint inhibitors and focuses on current strategies to identify and isolate neoantigen-reactive T cells as well as the clinical development of neoantigen-based therapeutics. The results suggest that maximal T-cell stimulation and expansion can be achieved with combination therapies that enhance antigen-presenting cells' function and optimal T-cell priming in lymph nodes.

Keywords:

References

1. Li Q, Ding Z-Y. The ways of isolating neoantigen-specific T cells. Front. Oncol. 10, 1347 (2020).
MedlineGoogle Scholar
2. Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev. Anticancer Ther. 15(9), 981–993 (2015).
Medline CASGoogle Scholar
3. Faghfuri E, Pourfarzi F, Faghfouri AH, Abdoli Shadbad M, Hajiasgharzadeh K, Baradaran B. Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin. Biol. Ther. 21(2), 201–218 (2021).
Medline CASGoogle Scholar
4. Faghfuri E, Shadbad MA, Faghfouri AH, Soozangar N. Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination. Immunotherapy 14(6), 475–488 (2022).
CASGoogle Scholar
5. Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol. Med. 18(4), 955 (2021).
Medline CASGoogle Scholar
6. Chen F, Zou Z, Du J et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J. Clin. Investig. 129(5), 2056–2070 (2019).
MedlineGoogle Scholar
7. Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18(4), 215–229 (2021).
MedlineGoogle Scholar
8. Liao J-Y, Zhang S. Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment. Front. Oncol. 11, 663264 (2021).
Medline CASGoogle Scholar
9. Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal. Transduct. Target. Ther. 8(1), 9 (2023).
Medline CASGoogle Scholar
10. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 348(6230), 69–74 (2015).
Medline CASGoogle Scholar
11. Vormehr M, Türeci Ö, Sahin U. Harnessing tumor mutations for truly individualized cancer vaccines. Annu. Rev. Med. 70, 395–407 (2019).
Medline CASGoogle Scholar
12. Turajlic S, Litchfield K, Xu H et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18(8), 1009–1021 (2017).
Medline CASGoogle Scholar
13. Yang W, Lee K-W, Srivastava RM et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat. Med. 25(5), 767–775 (2019).
Medline CASGoogle Scholar
14. Balachandran VP, Łuksza M, Zhao JN et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551(7681), 512–516 (2017).
Medline CASGoogle Scholar
15. Giannakis M, Mu XJ, Shukla SA et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15(4), 857–865 (2016).
Medline CASGoogle Scholar
16. Howitt BE, Shukla SA, Sholl LM et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1(9), 1319–1323 (2015).
MedlineGoogle Scholar
17. Zaravinos A, Roufas C, Nagara M et al. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. J. Exp. Clin. Cancer Res. 38(1), 364 (2019).
MedlineGoogle Scholar
18. Kiyotani K, Chan HT, Nakamura Y. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 109(3), 542–549 (2018).
Medline CASGoogle Scholar
19. Vita R, Overton JA, Greenbaum JA et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 43(D1), D405–D412 (2015).
Medline CASGoogle Scholar
20. Lu Y-C, Yao X, Crystal JS et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 20(13), 3401–3410 (2014).
Medline CASGoogle Scholar
21. Moeckel C, Bakhl K, Georgakopoulos-Soares I, Zaravinos A. The efficacy of tumor mutation burden as a biomarker of response to immune checkpoint inhibitors. Int. J. Mol. Sci. 24(7), 6710 (2023).
Medline CASGoogle Scholar
22. Yap KL, Kiyotani K, Tamura K et al. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin. Cancer Res. 20(24), 6605–6617 (2014).
Medline CASGoogle Scholar
23. Choudhury NJ, Kiyotani K, Yap KL et al. Low T-cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer. Eur. Urol. Focus 2(4), 445–452 (2016).
MedlineGoogle Scholar
24. Kato T, Park J-H, Kiyotani K, Ikeda Y, Miyoshi Y, Nakamura Y. Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. Oncotarget 8(37), 62029 (2017).
MedlineGoogle Scholar
25. Kiyotani K, Park J-H, Inoue H et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Oncoimmunology 6(2), e1278330 (2017).
MedlineGoogle Scholar
26. Akiyoshi T, Tanaka N, Kiyotani K et al. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br. J. Surg. 106(10), 1381–1392 (2019).
Medline CASGoogle Scholar
27. Akiyoshi T, Gotoh O, Tanaka N et al. T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer. Cancer Immunol. Immunother. 70(2), 509–518 (2021).
Medline CASGoogle Scholar
28. Strickland KC, Howitt BE, Shukla SA et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7(12), 13587 (2016).
MedlineGoogle Scholar
29. Matsushita H, Sato Y, Karasaki T et al. Neoantigen load, antigen presentation machinery, and immune signatures determine prognosis in clear cell renal cell carcinomaneoantigens and immune signature of ccRCC patients. Cancer Immunol. Res. 4(5), 463–471 (2016).
Medline CASGoogle Scholar
30. Vryza P, Fischer T, Mistakidi E, Zaravinos A. Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. Transl. Oncol. 38, 101788 (2023).
Medline CASGoogle Scholar
31. Rizvi NA, Hellmann MD, Snyder A et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348(6230), 124–128 (2015).
Medline CASGoogle Scholar
32. Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257), 207–211 (2015).
Medline CASGoogle Scholar
33. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
Medline CASGoogle Scholar
34. Kitsou M, Ayiomamitis GD, Zaravinos A. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. Int. J. Oncol. 57(1), 237–248 (2020).
Medline CASGoogle Scholar
35. Goodman AM, Kato S, Bazhenova L et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16(11), 2598–2608 (2017).
Medline CASGoogle Scholar
36. Samstein RM, Lee C-H, Shoushtari AN et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202–206 (2019).
Medline CASGoogle Scholar
37. Stenzinger A, Allen JD, Maas J et al. Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer 58(8), 578–588 (2019).
Medline CASGoogle Scholar
38. Subudhi SK, Vence L, Zhao H et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci. Transl. Med. 12(537), eaaz3577 (2020).
Medline CASGoogle Scholar
39. Miao D, Margolis CA, Vokes NI et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50(9), 1271–1281 (2018).
Medline CASGoogle Scholar
40. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res. 25(13), 3753–3758 (2019).
Medline CASGoogle Scholar
41. Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J. Natl. Compr. Canc. Netw. 15(2), 142–147 (2017).
MedlineGoogle Scholar
42. Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375(9), 819–829 (2016).
Medline CASGoogle Scholar
43. Peng W, Chen JQ, Liu C et al. Loss of PTEN promotes resistance to T Cell-mediated immunotherapy. Cancer Discov. 6(2), 202–216 (2016).
Medline CASGoogle Scholar
44. Miyauchi E, Matsuda T, Kiyotani K et al. Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations. Cancer Sci. 110(3), 867–874 (2019).
Medline CASGoogle Scholar
45. Koyama S, Akbay EA, Li YY et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 76(5), 999–1008 (2016).
Medline CASGoogle Scholar
46. Cristescu R, Mogg R, Ayers M et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362(6411), eaar3593 (2018).
MedlineGoogle Scholar
47. Inoue H, Park J-H, Kiyotani K et al. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 5(9), e1204507 (2016).
MedlineGoogle Scholar
48. Kato T, Kiyotani K, Tomiyama E et al. Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. Oncoimmunology 10(1), 1862948 (2021).
MedlineGoogle Scholar
49. Lee H-H, Wang Y-N, Xia W et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer cell 36(2), 168–178.e164 (2019).
Medline CASGoogle Scholar
50. Forget M-A, Haymaker C, Hess KR et al. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin. Cancer Res. 24(18), 4416–4428 (2018).
Medline CASGoogle Scholar
51. Andersen R, Donia M, Ellebaek E et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 22(15), 3734–3745 (2016).
Medline CASGoogle Scholar
52. Tran E, Robbins PF, Rosenberg SA. ‘Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18(3), 255–262 (2017).
Medline CASGoogle Scholar
53. Robbins PF, Lu Y-C, El-Gamil M et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19(6), 747 (2013).
Medline CASGoogle Scholar
54. Yossef R, Tran E, Deniger DC et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight 3(19), e122467 (2018).
MedlineGoogle Scholar
55. Zhang DK, Adu-Berchie K, Iyer S et al. Enhancing CAR-T cell functionality in a patient-specific manner. Nat. Commun. 14(1), 506 (2023).
Medline CASGoogle Scholar
56. Cruz-Ramos M, García-Foncillas J. CAR-T cell and personalized medicine. Adv. Exp. Med. Biol. 1168, 131–145 (2019).
Medline CASGoogle Scholar
57. Zhao Q, Jiang Y, Xiang S et al. Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front. immunol. 12, 658753 (2021).
Medline CASGoogle Scholar
58. Lennerz V, Fatho M, Gentilini C et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102(44), 16013–16018 (2005).
Medline CASGoogle Scholar
59. Cohen CJ, Gartner JJ, Horovitz-Fried M et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Investig. 125(10), 3981–3991 (2015).
MedlineGoogle Scholar
60. Cafri G, Yossef R, Pasetto A et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat. Commun. 10(1), 1–9 (2019).
MedlineGoogle Scholar
61. Theaker SM, Rius C, Greenshields-Watson A et al. T-cell libraries allow simple parallel generation of multiple peptide-specific human T-cell clones. J. Immunol. Methods 430, 43–50 (2016).
Medline CASGoogle Scholar
62. Martin SD, Wick DA, Nielsen JS, Little N, Holt RA, Nelson BH. A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer. Oncoimmunology 7(1), e1371895 (2018).
Google Scholar
63. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550–4557 (2011).
Medline CASGoogle Scholar
64. Prickett TD, Crystal JS, Cohen CJ et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol. Res. 4(8), 669–678 (2016).
Medline CASGoogle Scholar
65. Lu Y-C, Yao X, Li YF et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J. Immunol. 190(12), 6034–6042 (2013).
Medline CASGoogle Scholar
66. Stevanović S, Pasetto A, Helman SR et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356(6334), 200–205 (2017).
Medline CASGoogle Scholar
67. Tran E, Turcotte S, Gros A et al. Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer. Science 344(6184), 641–645 (2014).
Medline CASGoogle Scholar
68. Tran E, Robbins PF, Lu Y-C et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375(23), 2255–2262 (2016).
Medline CASGoogle Scholar
69. Zacharakis N, Chinnasamy H, Black M et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24(6), 724–730 (2018).
Medline CASGoogle Scholar
70. Carreno BM, Magrini V, Becker-Hapak M et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348(6236), 803–808 (2015).
Medline CASGoogle Scholar
71. Sahin U, Derhovanessian E, Miller M et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547(7662), 222–226 (2017).
Medline CASGoogle Scholar
72. Ott PA, Hu Z, Keskin DB et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547(7662), 217–221 (2017).
Medline CASGoogle Scholar
73. Keskin DB, Anandappa AJ, Sun J et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738), 234–239 (2019).
Medline CASGoogle Scholar
74. Hilf N, Kuttruff-Coqui S, Frenzel K et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565(7738), 240–245 (2019).
Medline CASGoogle Scholar
75. Tanyi JL, Bobisse S, Ophir E et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci. Transl. Med. 10(436), eaao5931 (2018).
MedlineGoogle Scholar
76. Shainheit M, Champagne D, Santone G et al. 413 GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors. J. Immunother. Cancer 8(Suppl. 3), (2020).
Google Scholar
77. Cohen RB, Johnson M, Twardowski P et al. Broad immunogenicity from GEN-009, a neoantigen vaccine using ATLASTM, an autologous immune assay, to identify immunogenic and inhibitory tumor neoantigens. J. Immunother. Cancer 7(Suppl. 1), P420 (2019).
Google Scholar
78. Blazquez A, Rubinsteyn A, Kodysh J et al. A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies. J. Clin. Oncol. 37(Suppl. 15), (2019).
Google Scholar
79. Ott PA, Hu-Lieskovan S, Chmielowski B et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183(2), 347–362.e324 (2020).
Medline CASGoogle Scholar
80. Naing A, Hu-Lieskovan S, Govindan R et al. An open-label, phase Ib study of NEO-PV-01+ adjuvant with nivolumab in patients with melanoma, non-small cell lung carcinoma, or transitional cell carcinoma of the bladder. J. Clin. Oncol. 35(Suppl. 15), (2017).
Google Scholar
81. Braiteh F, Lorusso P, Balmanoukian A, Klempner S, Camidge D, Hellmann M. A phase Ia study to evaluate RO7198457, an individualized neoantigen specific immunotherapy (iNeST), in patients with locally advanced or metastatic solid tumors. Presented at: Proc. Am. Assoc. Cancer Res. 80(Suppl. 16), CT169 (2020).
Google Scholar
82. Lopez JS, Camidge R, Iafolla M et al. A phase Ib study to evaluate RO7198457, an individualized neoantigen specific immunotherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Res. 80(Suppl. 16), CT301 (2020).
Google Scholar
83. Burris HA, Patel MR, Cho DC et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. J. Clin. Oncol. 37(Suppl. 15), 2523–2523 (2019).
Google Scholar
84. Peng M, Mo Y, Wang Y et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol. Cancer 18(1), 1–14 (2019).
MedlineGoogle Scholar
85. Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat. Med. 25(10), 1488–1499 (2019).
Medline CASGoogle Scholar
86. Ma L, Dichwalkar T, Chang JY et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365(6449), 162–168 (2019).
Medline CASGoogle Scholar
87. Wu Y, Feng L. Biomaterials assisted construction of neoantigen vaccines for personalized cancer immunotherapy. Expert Opin. Drug Deliv. 20(3), 323–333 (2023).
Medline CASGoogle Scholar
88. Li X, Zhang Y, Wu X et al. In situ antigen‐capturing nanochaperone toward personalized nanovaccine for cancer immunotherapy. Small 18(32), 2203100 (2022).
CASGoogle Scholar
89. Li J, Li J, Peng Y, Du Y, Yang Z, Qi X. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J. Control Release 353, 423–433 (2023).
Medline CASGoogle Scholar
90. Liu C, Liu X, Xiang X et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat. Nanotechnol. 17(5), 531–540 (2022).
Medline CASGoogle Scholar
91. Alberto H. Neoantigens: unleashing the power of personalized cancer immunotherapy. J. Oncol. Transl. Res. 9(1), (2023).
Google Scholar

Vol. 21, No. 1

Metrics

Downloaded 124 times

History

Received 15 May 2023

Accepted 31 October 2023

Published online 13 December 2023

Published in print January 2024

Information

Keywords

Financial disclosure

This study was supported and funded by the Deputy of Research and Technology, Ardabil University of Medical Sciences, IR.ARUMS.REC.1401.250. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Conflict of interests disclosure

The author has no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

PDF download